Applications of Machine Learning in Drug Discovery II: Biomarker Discovery, Patient Stratification and Pharmacoeconomics by Cassidy, John W.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Applications of Machine Learning 
in Drug Discovery II: Biomarker 
Discovery, Patient Stratification 
and Pharmacoeconomics
John W. Cassidy
Abstract
Cancer remains a leading cause of morbidity and mortality around the 
world. Despite significant advances in our understanding of the pathology of 
the disease, and the substantial public and private investment into treatment 
development, late-stage patients often exhaust therapeutic options. Indeed, in the 
US alone, there were >1.7 million new cancer diagnoses and >600,000 cancer-
associated deaths in 2019. As biology in general and cancer research in particular 
become ever richer in data, we explore the role of machine learning (ML) in 
changing the cancer drug development landscape. In the first part of this analy-
sis, we focussed on ML for target identification and drug design. We discussed 
the growing need for ML-based analysis as we enter an age of clinical -omic 
data and provided a primer to ML-based techniques for the non-statistician/
mathematician. In this chapter, we will explore the problem of tumour hetero-
geneity together with the role of ML in the discovery and development of cancer 
biomarkers and for clinical trial design. We end with a brief consideration of the 
economics of personalised cancer treatment.
Keywords: machine learning, biomarker discovery, oncology
1. Introduction
The cancer therapeutic market was estimated to reach $98.9 billion USD in 
2018, with a compounded annual growth rate of 7.7%. The cost of individual cancer 
drugs is similarly rising at a rate well above inflation. Ipilimumab, for example, was 
priced at $120,000 on launch, despite providing an overall survival benefit of just 
4 months. More generally, if we correct for inflation and increased survival benefit, 
the average cost of new cancer therapies increased at $8500 per year from 1995 to 
2013 [1]. If we continue along this path of yearly incremental price increases in new 
therapies approved, while not seeing associated health benefits, public opinion may 
begin to further question the moral standing of the pharmaceuticals industry [2].
However, there exists a profound conflict at the heart of the pharmaceutical 
industry. The efficiency of the drug development process is falling, leading to 
higher costs to be recovered per approved drug. At the same time, research into 
the biological underpinnings of disease are making it clear that pathologies once 
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thought of as a single disease are incredibly heterogeneous in nature [3]. In such 
cases, personalised medicine may be the best method for treating diseases like 
cancer, which could shrink the available markets for each individual drug.
Cancer has been known to be heterogeneous since experimental pathologists 
began to study tumour in detail at the turn of the nineteenth century. First, dif-
ferences in cellular morphology were described [4], followed by surface marker 
expression [5] and later growth rates [6] and response to therapy [7]. Recently, high 
throughput profiling of DNA, RNA and protein expression in human cancers has 
helped uncover the true scale of this diversity [8]. For example, early work in breast 
cancer enabled stratification of patients based on the presence of oestrogen receptor 
alpha (ERα), which led to the successful targeting of tamoxifen for ERα-positive 
(ERα+) patients [9]. More recent work has enabled comprehensive stratification of 
breast and other cancers [8, 10]. In breast cancer, a 50-gene signature (PAM50) can 
now be used to stratify patients into four intrinsic subtypes (luminal A, luminal B, 
HER2-enriched and basal-like) with distinct clinical outcomes [11, 12]. Taking this 
stratification effort further, researchers at the University of Cambridge integrated 
copy number (CN) data with transcriptomics to uncover 11 distinct Integrative 
Clusters of breast cancer [10].
Patient stratification improves the taxonomy of cancer, which is the initial step 
towards better understanding of the drivers of tumour growth and consequently 
towards improved precision medicines [13]. However, as our appreciation of strati-
fication and heterogeneity increases, the challenge for pharmaceutical companies is 
to develop an economic model that enables them to provide personalised treatment 
to patients at a sustainable cost.
In practice, the efficiency of the drug development process has been dropping for 
a number of years. The average time for taking a new therapeutic to market is often 
stated as 10 years; however, in reality this often ranges from 3 to 20 years [14]. If we 
consider the average cost of developing a new drug, in 2014 the Tufts Center for the 
Study of Drug Development estimated this at $2.6 billion [14]. A large proportion of 
this cost is associated with a 90% attrition rate in Phase I–Phase III trials; $2.6 billion 
covers the nine failures for every one approved drug. However, on an individual 
pharmaceutical company basis, the picture can get even worse. AstraZeneca has 
recently spent an average of $11 billion per registered drug [15]. Considering (1) high 
upfront costs, (2) high risk of overspending and failure and (3) the possibility of very 
long development time frames, pharmaceutical companies must price in the cost of 
capital to their calculation of drug price. $11bn spent over 20 years, when that money 
could have been generating 10% annual returns in a stock market index, means that 
it is not uncommon for pharmaceutical companies to wish to generate many tens of 
billions of dollars in lifetime drug sales.
Thankfully, we are entering a world of big data biology and techniques like 
machine learning (ML) can help us increase efficiency in the drug discovery and 
development process. In the first part of our analysis, Applications of Machine 
Learning in Drug Discover I: Target Discovery and Small Molecule Drug Design, we 
discussed how molecular target identification and small molecule lead optimisation 
can be improved though computational techniques. However, early development 
accounts for a relatively small proportion of the total costs associated with drug 
development. Phase III trials alone, for example, on average cost over $100 million 
[16]. If we are to improve efficacy in drug development, we must improve late-stage 
clinical trials and stratification of patients post market approval.
In this chapter, we discuss how ML is allowing high personalisation of treatment 
strategies.
First, we consider the causes of tumour heterogeneity, its genomic underpin-
nings and the latest research into patient stratification. Next, we consider the 
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discovery of predictive biomarkers for patient stratification in clinical trials and 
post market approval. Thankfully, the same techniques we use to improve trials 
can also be used to fulfil precision oncology and deliver better patient outcome. 
As the number of drugs increases, we may also be able to use repurposing and 
repositioning to make up for lost revenues from personalisation and increase 
profitability of old drugs. Lastly, we discuss computational pathology as one of 
the most obvious early uses of ML in cancer diagnosis. We end with a forward-
looking discussion of the future of precision oncology and what this means for the 
pharmaceutical industry.
2. The causes and consequences of tumour heterogeneity
Cancer is a disease of the genome [13, 17]. Through the normal course of ageing, 
cells acquire somatic mutations as a consequence of intrinsic processes or the expo-
sure to exogenous mutagens. These changes in the cellular DNA can directly influ-
ence the structure and function of transcribed proteins, and, in some cases, confer 
a survival advantage (‘fitness’), on the cell. Peter Nowell postulated in 1976 that 
heterogeneous fitness in a niche could lead to Darwinian competition and selection 
among clones [18], and that successive clonal expansion was the origin of a tumour. 
This theory was supported by early evidence that genetic aberrations were the cause 
of a tumour’s phenotypic traits [19] and more recent genomics research [8, 20].
It is now accepted that tumours harbour various layers of genomic complexity 
and the resultant heterogeneity can have profound effects on disease progression. 
Moreover, genomic instability, which fuels the diversity essential for any Darwinian 
process is intertwined with both the development and maintenance of tumour 
heterogeneity, and the clinical consequences thereof [21, 22]. Indeed, both inter- 
and intratumour heterogeneity can be explained by the genomic instability inherent 
to a tumour’s biology and the sequential acquisition of driver mutations. Though 
changes in a tumour’s microenvironment (e.g. increase in inflammation or immune 
cell infiltrate) or epigenetic regulation (e.g. MLH1 promotor methylation in micro-
satellite unstable CRC) are undoubtedly required to transform a clonal expansion of 
benign cells into a malignancy [17, 23].
Interestingly, a series of studies over the last couple of years from the Sanger 
Institute have shed new light onto the clonal origins of human cancers. First, in 
2013, it was shown by Alexandrov and colleagues that distinct mutational processes 
(e.g. exposure to tobacco smoke and exposure to ultraviolet light) led to distinct 
mutational signatures in human cancer [24]. Next, Martincorena and colleagues 
showed that outwardly normal human skin not only had traces of these mutational 
signatures but in some cases harboured daughter cells of past clonal expansion 
events [25]. This was later corroborated in other tissues including the oesophagus 
[26]. It was not until 2020, when a study by Colom et al. [27] was published that 
we had any insight into what differentiated these clonal populations from bona 
fide premalignant clones. In an elegant study, the authors showed that when an 
expanding mutant clone occupied the same niche as one of similar ‘fitness’, each 
clone’s proliferative advantage decreases, and the niche reverts towards balanced 
proliferation and differentiation that characterises normal tissue homeostasis [27]. 
Such studies highlight how far we have come in our understanding of the causes 
of tumour heterogeneity since Peter Nowell’s seminal work in 1976 [18], and how 
much we may still have to learn.
Tumour heterogeneity has a very real clinical consequence: chemotherapy and 
targeted agents do not have uniform efficacy. This holds across malignancies of 
different subtype and even between cells of the same tumour [28]. As mentioned, 
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for example, breast cancers can be clinically stratified based on heterogeneity in the 
presence of hormone receptors (ERα/PR) and HER2, the presence of which define 
treatment recommendation.
As the cost of DNA sequencing and other high throughput profiling technologies 
continues to drop, our taxonomy of cancer is becoming ever more nuanced [29]. 
Early genomic classifications based on single parameters have evolved into complex 
integrative methodologies designed to capture heterogeneity across multiple levels, 
such as the 11 Integrative Clusters of breast cancer defined by Curtis et al. [10]. 
Indeed, as multi-parameter stratification improves, we are beginning to stratify 
both breast [30] and colorectal cancers [31] based on immune infiltrates and immu-
nogenomic signatures. Such classification will have a direct influence on our use of 
novel immunotherapies [32].
A second clinical consequence of tumour heterogeneity is in the development of 
resistance to targeted therapies [33]. Typically, this results from the outgrowth of 
specific pre-existing populations within a tumour rather than from de novo evolu-
tion [3, 34]. It therefore stands to reason that the higher the more pronounced the 
clonal heterogeneity in a tumour, the wider the pool from which drug-resistant 
clones may evolve [3]. There exists a fine balance within a tumour between waves of 
clonal expansion by hyper-fit cells, and the maintenance of subclones from which 
resistance can develop. Such an association between tumour heterogeneity and drug 
resistance has been noted in ovarian [35] and oesophageal [21] cancers.
Evolution occurs when spatial or temporal selective pressure is applied to popu-
lations with differential fitness, which is itself underwritten by heritable features. 
Drug treatment induces evolution of clonal populations within a tumour, which can 
provide a niche into which resistant clones can grow. Counterintuitively, however, 
anti-cancer therapies do not necessarily lead to a reduction in overall clonal diver-
sity or tumour genomic heterogeneity [36]. For example, in a study of 47 breast 
cancer patients, strong changes in cellular phenotype were seen before and after 
chemotherapy, with no corresponding changes in genetic diversity, implying that a 
shift in the epigenomic landscape had resulted from exposure to chemotherapeutic 
selective pressures [37]. In addition, several studies have identified the role of 
transient epigenetic states in the resistance to cancer therapy. For example, Sharma 
et al. consistently detected a subpopulation of cells with >100-fold reduced erlotinib 
sensitivity across a panel of eight cancer cell lines [38]. The authors found that this 
drug-tolerant phenotype was transiently acquired and lost by individual cells within 
the population in a process linked to IGF-1 signalling and histone demethylase-
mediated chromatin remodelling [38].
Genomic instability is the driving force of tumour heterogeneity. Although 
intratumour heterogeneity is linked with poor patient outcome, genomic instabil-
ity is only associated with poor prognosis to a point. A recent study examined 
1000 treatment-naïve tumours and found that the total number of genomic clones 
had significant association with overall survival [39]. However, the authors note 
that high clone number was only indicative of survival up to a maximum clonal 
diversity of four. Indeed, a diversity of more than four subclones was associated 
with longer overall survival [39, 40]. The authors used a 10% cell frequency cut 
off in their studies, yet, they are rare clonal populations which are thought to have 
evolved most recently [41] and may be more associated with resistance to targeted 
therapy [42–44]. This could go some way to explaining the apparent discrepancy 
seen between this, and other studies.
Hence, both intra- and intertumour heterogeneity have profound clinical conse-
quences in terms of differential response to therapy, development of drug resistance 
and disease progression. Beyond stratified medicine, a better understanding of 
the causes and consequences of clonal heterogeneity within a tumour will allow a 
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deeper understanding of the emergence of drug resistance. New analysis tools such 
as the REVOLVER package could empower researchers to stratify patient groups 
based on the basis of how their tumour evolved [45, 46] and perhaps allow predic-
tion of a tumour’s evolutionary trajectory and a corresponding therapeutic strategy. 
Moreover, a greater understanding of genomic instability and its contribution to 
treatment resistance, and sensitivity, is needed.
3. Predictive biomarkers for personalised cancer care
As discussed, late-stage clinical trials are one of the most expensive, in terms 
of resource spending and time, in the total drug development lifecycle. Although 
many predictive models are mentioned in the literature, few have been validated 
in clinical trials. Various limitations around model performance, validation and 
dataset availability are currently limiting translation [47].
As one of the key clinical endpoints, drug sensitivity or efficacy would be one of 
the most important metrics to predict from preclinical data in order to improve the 
clinical success rate of drugs. In terms of real-world evidence, a handful of groups 
have now published case studies where biomarkers derived from ML-driven predic-
tive modelling have played a central role in the discovery and development of new 
therapeutic agents [48–50].
In one such case study, Li and colleagues built drug sensitivity models from 
cancer cell lines treated with erlotinib [an EGFR protein kinase inhibitor approved 
for NSCLC patients with activating mutations: exon 19 deletion (del19) or exon 21 
(L858R) substitution] and sorafenib (a non-specific kinase inhibitor approved for 
advanced renal cell carcinoma) [48, 51]. Models were then used to stratify patients 
in the BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung 
Cancer Elimination) clinical trial [48, 52], with identified biomarkers backwards 
justified with knowledge of the mechanism of action of each kinase inhibitor drug. 
Crucially, combining biomarker-driven adaptive trials such as BATTLE with basket 
trials (tissue of origin agnostic), we can move towards truly data-driven person-
alised oncology. Indeed, the FDA approved pembrolizumab [a programmed cell 
death 1 (PD1) inhibitor] in 2017 for tumours of a specific genetic background rather 
than site of origin [53]. This is the first instance of a cross-indication approval based 
solely on a genetic biomarker and highlights the need for further study in drug 
repurposing and data-driven biomarker discovery for the future of genomic cancer 
medicine.
To address some barriers to model translation into clinical practice, several 
community efforts have been attempted to help evaluate and standardise ML-based 
models. For example, the FDA launched a validation initiative for benchmarking 
ML models for predicting clinical endpoint from RNA expression data [54]. In this 
Microarray Quality Control II (MAQC II) initiative, teams were tasked with gener-
ating predictive models for several clinical endpoints in a multiple myeloma dataset. 
The most effective method used a univariant Cox regression model to identify a 
gene signature associated with individuals at high risk of low overall survival [55]. 
Though the authors note that arbitrary cut offs in overall survival may have limited 
effectiveness (24 months was the cut off for high risk, despite overall survival being 
a continuous variable suited to Cox modelling). A similar approach can be taken 
with breast cancer gene expression data to predict overall survival as a continuous 
variable [46]. Interestingly, the multiple myeloma prognostic biomarker developed 
was later independently validated by several groups [56–58].
The NCI-DREAM challenge was a similar community-driven effort to provide 
standardised datasets for benchmarking ML models [59]. In this case, models were 
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trained on a dataset consisting of RNA expression profiles, mutation data (from 
SNP array), protein array data, exome sequencing and DNA methylation, from 
35 breast cancer cell lines treated with 31 anti-cancer drugs. The models then had 
to predict outcome from a blinded dataset of 18 cell lines with the same 31 drugs. 
The best performing models were invariably regression based: such as the kernel 
method, nonlinear regression, regression trees, sparse linear regression, partial 
least squares regression, principal component regression and ensemble methods 
[59]. The dataset continues to be used to benchmark a variety of models such a 
random forest ensemble frameworks [60], group factor analyses [61] and other 
approaches [62, 63].
Our group has approached the problem of data availability by combining 
datasets from multiple sources (DNA, RNA; patients, cell lines) using variational 
autoencoders (VAE) optimised to compress somatic mutations while maintain-
ing signal [64]. We trained our models on somatic profiles from 8062 Pan-Cancer 
patients from The Cancer Genome Atlas and 989 cell lines from the COSMIC cell 
line project and compared two different neural network architectures for the VAE: 
multilayer perceptron (MLP) and bidirectional LSTM. We found that the size of the 
latent space did not have a significant effect on the VAE learning ability and showed 
that the model maintained representations of 64 dimensions and held the same 
predictive power as the original 8298-dimension vector, through prediction of drug 
response [64].
Stratification of cancer patients into molecular subgroups in an effort to predict 
drug sensitivity is a common practice. As discussed previously, one such method 
integrated copy number, gene expression and mutational data from >2000 breast 
cancers in order to define 11 ‘Integrative Subtypes’ [10]. In a later study from the 
same authors, a biobank of breast cancer xenografts (PDX models) was established 
and high throughput combinatorial drug screens were performed on xenograft-
derived tumour cells [65, 66]. The authors observed differential sensitivity between 
PDX models of different integrative clusters and even observed drugs with similar 
molecular mechanisms of action to cluster together [67]. However, in general the 
reproducibility and clinical relevance of unsupervised clustering is poor. This is 
thought to be attributable to the routine analysis of small cohorts consisting of 
fewer than 100 patients, together with the use of biased traditional consensus 
clustering techniques. In our study, we combined multiple RNA expression data-
sets and developed a robust Monte-Carlo Consensus Clustering program, called 
PDACNet. We identified six biologically novel subtypes that were reproducible 
across datasets [67].
ML-based predictive biomarkers have also seen recent advances outside of the 
oncology space. Leveraging the rich UK biobank dataset, for example, Paré and 
colleagues were able to explain 46.9% of overall polygenetic variance for height 
and 32.7% for body mass index (BMI) through the building of gradient boosted 
regression trees based on SNP arrays [68]. Expanding this beyond SNP arrays, 
Khera and colleagues built ML-driven polygenic risk score to identify individuals 
with greater than threefold increased risk for coronary artery disease (80% of the 
population were found to be genetically predisposed), atrial fibrillation (6.1%), 
type 2 diabetes (3.5%), inflammatory bowel disease (3.2%) and breast cancer 
(2.5%) [69].
Building from polygenic risk scores to multi-omic profiling, Tasaki and col-
leagues studied clinical remission in rheumatoid arthritis patients by longitudinal 
monitoring of the drug response at multi-omics levels in the peripheral blood of 
patients [70]. This high dimensional phenotyping, coupled with ML-led analysis, 
enabled the authors to uncover signatures independently associated with resistance 
to treatment and with no known associated with previously discovered disease 
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severity indexes. This technique could be expanded to a quantitative measure of 
molecular remission useful in a clinical setting.
Perhaps among the most exciting use of ML in driving our understanding of 
human pathophysiology is in the building of in silico experimental models in which 
researchers may perturb regulatory networks at will and illicit real (but simulated) 
biological responses. Towards this goal, Way and Greene built a VAE model trained 
on over 10,000 tumours across 33 different cancer types from The Cancer Genome 
Atlas (TCGA) named ‘Tybalt’ [71]. The authors showed Tybalt could capture 
biologically relevant features and model cancer gene expression under perturba-
tion. Though a lot of future work is needed, such system-based approaches could 
1 day aid in prediction of specific activated expression patterns that resulted from 
genetic changes or perturbation by therapeutics. Combined with discussed survival 
and outcome-based predictive models, we could then model treatment response to 
myriad theoretical combination therapies in silico.
Though the discussed examples of ML-led biomarker discovery are promising, 
there are several key barriers to adoption that still require work. End clinical users, 
for example, cite interpretability of the classifier as a critical barrier for clinical 
adoption. We must also validate our models in the context of multi-site, multi-
institutional datasets to demonstrate their generalisability.
4. Adaptive clinical trials
As stated, the most capital and time-intensive part of brining a new medicine 
to market is arguably the late-stage clinical trial. Phase III studies, for example, can 
run over multiple years and across multiple clinical centres and cost upwards of 
$100 million. As advanced statistical techniques gain traction, and as our under-
standing of biomarkers of response improves, we could see dramatic overhaul in the 
way clinical trials are carried out.
One set of designs of particular interest to this chapter are the adaptive clinical 
trials. Adaptive designs utilise results accumulating through the course of a trial 
to modify the trial’s course in accordance with pre-specified rules. Pre-specified 
changes to the trial design may include refining the sample size, abandoning treat-
ments or doses, changing the ratio of patients in each arm (e.g. placebo arm), focus-
sing recruitment efforts in patients most likely to benefit or stopping the entire trial 
early either successfully or due to a lack of efficacy [72]. In this way, adaptive trials 
can be more capital and time efficient, more informative and more ethically accept-
able than those of a traditional fixed design.
As adaptive trials could theoretically rely on sequential decision-making, they 
could be particularly well suited to ML-based efficiency gains. Indeed, there is 
a class of algorithms inspired by clinical trials themselves, known as Multi-Arm 
Bandit (MAB) algorithms [73]. MABs are useful when a fixed and limited set of 
resources must be allocated between alternative (competing) choices in a way that 
maximises total reward, even though the reward for each choice is not immediately 
known to the MAB. Thus, MABs can find a set of choices to maximise reward with 
incomplete information through reinforcement learning. Given the fixed nature of 
a classical clinical trial, in which groups patients are given treatments sequentially 
one after another, MAB algorithms could be natural candidates to help guide 
further phases of drug testing [47, 74].
As the simplest form of a MAB system, we can consider a Phase III clinical 
study to comprise K treatment arms, each with an unknown probability of success 
(p1, p2, … pK) and a reward (Xt) equal to 1 if treatment succeeds and 0 if treatment 
fails. The choice of treatment for the tth patient depends on each of the previously 
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given treatments and their observed outcomes. The trial’s data-driven adaptiv-
ity could therefore allow statistical power for each arm to be reached with fewer 
patients by incorporating automatic interim analysis in the treatment decision. 
Theoretically, such a trial would be resource efficient across all parameters (time, 
economic, minimise side effects, maximise patient life) [74].
Despite the theoretical promise of adaptive trials, clinical uptake has been slow. 
This could be due to statistical requirements for traditional trials, for example 
balancing prognostic covariates in each arm [74], or could be due to practical dif-
ficulties such as the significant delay in feedback on treatment effectiveness [75]. It 
is for this reason that we can look forward to the maturation of technologies such as 
the real-time monitoring of treatment effectiveness pioneered by companies such 
as Cambridge Cancer Genomics.
5. Balancing the economics and promise of personalised oncology
Even as our understanding of the heterogeneity in cancer makes it ever more a 
part of the need for personalised treatment strategies, and as our computational 
tools begin to make this possible, a significant barrier to adoption is becoming 
apparent: the cost of personalised medicine in oncology is increasing [76]. There 
exists a profound conflict at the heart of precision oncology between the varied and 
contrasting priorities of the pharmaceutical industry, local and national govern-
ments, international medical community, and patients, which needs to be reviewed 
and balanced. Even as the stated aims of each stakeholder align, individual incen-
tive sets around target patient populations, the need to increase revenues and 
offset inefficiencies and the need to personalise treatment plans must be aligned if 
precision oncology is to become truly widespread.
It is no secret that the financial burden of cancer to the global economy is 
significant, perhaps more surprising is the personal economic costs. In the UK, 
where healthcare is free at the point of use, a cancer diagnosis results in a net loss 
to an individual of >£570, and in the US, a diagnosis increases the likelihood of 
bankruptcy by 250% [76]. Aside from direct costs associated with health insur-
ance deductibles and co-pays (e.g. in the US) and ancillary spending (e.g. in the 
UK), cancer is among the most expensive diseases to manage across the healthcare 
ecosystem. In particular, the last decade or so has seen a substantial increase in the 
direct costs of cancer medicine. At the turn of the twenty-first century, the average 
annual cost of a new anti-cancer therapy was a little under $10,000, by 2016 this 
had risen to $100,000 for the same treatment duration [77]. Proponents of the 
pharmaceutical industry would point out that treatment modalities have increased 
in complexity significantly in the same period; however, there is little evidence that 
improvements in patient outcomes have kept pace with the increase in costs.
Indeed, when viewed in terms of Quality Adjusted Life Years (QALYs), the incre-
mental gain from new treatment modalities such as targeted and antibody therapies 
launched between 1999 and 2011 is 0.25 QALYs [78]. To put this in context, the 
average cost per QALY in the UK across all treatments is £13,000 and the threshold 
for approving treatments not intended for oncology by the National Institute for 
Clinical Excellence (NICE) is £20,000–£30,000. Moreover, beyond the cost of the 
drug itself, new treatment modalities are also associated with ancillary costs, for 
example, in companion diagnostics, development costs, and relevant associated 
technology. Personalised oncology is often seen as a saving grace in terms of making 
the high-quality cancer care sustainable. However, it is vital to understand the cost 
drivers in the current management of cancer and how these may change in a world 
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of widespread personalised treatment in order to improve or maintain value for 
money in the future of cancer care.
Fundamentally, in order to bias the QALY calculation in favour of cost-
effectiveness, we must either (1) improve targeting of drugs to only those patients 
who receive clinical benefit or (2) ensure that efficiency of the drug development 
process increases, to avoid fixed R&D costs being spread over a smaller patient 
population. Therefore, if precision oncology has the potential of improving the 
efficacy of drug targeting, we must look to cost-saving efficiencies in the drug 
development process.
Clearly, a key driver of the increasing cost of cancer care is the reduction in R&D 
efficiency in pharmaceuticals companies; indeed, this is ingrained in our collective 
understanding of the industry that has even been dubbed ‘Eroom’s Law’ [79]. It 
has long been argued that all the ‘low hanging fruit’ (i.e. all the easy targets) has 
long since been ‘picked’. However, this assumption belittles the fact that of the $2.6 
billion it costs to develop a new drug, a large proportion of this cost is associated 
with a 90% attrition rate in Phase II–Phase III trials [14]. Nevertheless, there is a 
real danger that the majority of recurrently mutated targets in cancer, for example 
EGFR, have already been targeted and any new therapies can only hope to pro-
vide incremental benefit beyond what has already been done. Thankfully, as new 
avenues of biology are explored, such as immune disruption by tumours, or new 
targeting modalities are discovered, new targets become available.
A potential avenue for improving the efficiency of drug development comes 
from considering manufacturing practices. The past two decades have seen a shift 
from small molecules to larger and more complicated biotherapies such as monoclo-
nal antibodies. The manufacturing methods of biotherapies are considerably more 
complicated and expensive than traditional small molecule therapies, which could 
in part account for the increasing cost of the end product. However, the efficiency 
of manufacture of biopharmaceuticals has increased dramatically over the same 
period: with typical yields increasing from 1 to 2.5 g/l during the period 2001–2014 
[80]. The complexity of manufacture also creates an additional barrier to entry for 
new drug manufacturers. There is a real concern that identical production process 
will not equate to identical products, this could protect against generic manufactur-
ers entering the market as soon as the initial patient protection has lapsed. Indeed, 
regulators have introduced regulatory processes for so-called biosimilars much 
costlier and more involved than for generics for small molecules.
An alternative explanation for the rising cost of cancer drugs, and one that is 
perpetuated by the media, is based entirely on market forces: that is the cost of can-
cer drugs increases because that is what the market is willing to tolerate. Proponents 
point to Orphan Drugs developed in the early 2000s. Initially priced in excess of 
$100,000 a year, the initial price was protested but inevitably paid. In terms of 
economic theory, this was a signal to the market of price elasticity and the willing-
ness to pay more for health [1]. Though comprised of well-meaning individuals, 
pharmaceutical companies are corporations with a legal obligation to maximise 
value for their shareholders. A slightly more palatable theory simply points to the 
reimbursement period: cancer is an acutely managed disease, treated for 6 months 
before the patient either recovers or, sadly, passes away. Unlike with chronic 
medications, therefore, the entire R&D costs of that drug must be paid back over a 
relatively short period of treatment time. This, of course, raises the effective price.
Clearly the balance of incentives in healthcare is a complicated problem. The 
danger is that precision oncology has the potential to increase some of these compli-
cations. If we are to see widespread adoption of more personalised medicine, then 
care must be taken to address inefficiencies in the pharmaceutical development 
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process. Otherwise, governments and patients may be left with an unpalatable bill 
for marginally improved health outcomes.
6. Summary
The estimated global incidence of all cancer types in 2015 was 17.5 million [81]. 
Fourteen per cent of all deaths in 2005 were due to cancer, which increased to 16% 
in 2015 [82]. In combating cancer, we have created a global industry of research 
institutes, pharmaceutical companies and specialist hospitals. This industry is 
currently failing to keep up with the rising global cancer burden and suffers from 
unprecedented inefficiencies. To solve this problem, we must incorporate technolo-
gies such as ML into the clinical care pathway. It is our opinion that investment 
should be focussed on the development of predictive biomarkers for treatment 
outcome, which take account of tumour heterogeneity and evolution. If we are to 
beat cancer, we should begin to look at it as a highly heterogeneous and dynamic 
disease that requires a more sophisticated treatment paradigm. In particular, we 
must be cognisant of tumour evolution and develop biomarkers suitable for the 
growing field of adaptive oncology.
Tumour evolution has been a key conceptual framework in cancer biology since 
it was first put forth by Peter Nowell in 1976 [18]. The theory postulates that cancers 
arise from a single cell that has a selective advantage over its neighbours and that 
cancer can be understood based on the evolutionary principles of selection and 
adaptation originating from this ancestral cell. Over time, cells within the tumour 
continue to adapt and bestow on the tumour whole, specific traits described as 
the Hallmarks of Cancer [22, 83]. These ideas have been developed using many of 
the concepts first established in evolutionary biology [84, 85], considering cancer 
as a disease of multicellular organisms in constant balance between Darwinian 
selection acting on the level of a single cell and the need for coordination between 
multiple cells for the good of the organism [86, 87]. From this perspective, cancers 
occur when an individual cell behaves in an autonomous manner, escaping from the 
mechanisms in place to coordinate cell behaviour [88].
The classic model of carcinogenesis describes multiple, successive clonal 
expansions driven by the accumulation of genomic changes or ‘mutations’ that are 
preferentially selected by the tumour environment [89]. However, it is important 
to note that natural selection acts on phenotypes rather than genotypes. Indeed, 
selection can be transient, favouring a specific phenotype in response to fluctuating 
changes in microenvironment. Indeed, recent work has uncovered monogenetic 
clonal expansion of phenotypic clones responsible for tamoxifen resistance in breast 
cancer [90] and chemotherapeutic resistance in CRC PDX models [91, 92].
More broadly, tumour evolution and resultant heterogeneity have been linked 
to several clinically important facets of cancer [10, 93], but are currently under-
served in terms of clinical translation. ML and the age of big biological data give 
us the necessary power to address this problem, and the clinical and the financial 
need is now.
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